Toshihisa Kimura Tamotsu Togawa Kenji Onishi Atsushi Iida Yasunori Sato Takanori Goi
10.1177/2324709620970736
J Investig Med High Impact Case Rep
2020 Jan-Dec;8:2324709620970736.
imatinib mesylate peritoneal metastases secondary resistance small intestinal gists tumor rupture
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/33228387/
Antineoplastic Agents / therapeutic use Gastrointestinal Neoplasms / drug therapy Gastrointestinal Stromal Tumors / drug therapy Imatinib Mesylate / therapeutic use Peritoneal Neoplasms / drug therapy
Antineoplastic Agents / therapeutic use Gastrointestinal Neoplasms / drug therapy Gastrointestinal Stromal Tumors / drug therapy Imatinib Mesylate / therapeutic use Peritoneal Neoplasms / drug therapy Case Reports Combined Modality Therapy Gastrointestinal Neoplasms / pathology Gastrointestinal Neoplasms / surgery Gastrointestinal Stromal Tumors / pathology Gastrointestinal Stromal Tumors / surgery Humans Male Middle Aged Neoplasm Recurrence, Local Peritoneal Neoplasms / secondary Treatment Outcome Antineoplastic Agents Imatinib Mesylate
PMC7691891
33228387
Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report
2020